Pure Global
NCT04657328

Prospective Multicenter Study on Clinical Application of Sonazoid in Breast Tumor

Contrast-enhanced Ultrasound in Breast Tumor by Sonazoid
Chinese PLA General Hospital·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ultrasound
Study type
Observational
Sponsor & location
Primary sponsor
Chinese PLA General Hospital
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Aug 15, 2020
End date
Oct 01, 2021
Enrollment
181 participants
Primary outcome

Diagnostic performance of contrast-enhanced ultrasound in breast tumor by Sonazoid.

Summary

Sonazoid as a new generation of ultrasound contrast agent.This study based on the features of
 Sonazoid specific angiography and high mechanical index,the role of Sonazoid in the
 differential diagnosis of breast benign and malignant tumors was explored.

ICD-10 classifications
Abnormal ultrasonic finding on antenatal screening of motherAntenatal screening for malformations using ultrasound and other physical methodsAntenatal screening for fetal growth retardation using ultrasound and other physical methodsOther diagnostic agentsExamination of ears and hearing
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04657328
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04657328 through Pure Global AI's free database. This phase not specified trial is sponsored by Chinese PLA General Hospital and is currently Recruiting. The study focuses on Ultrasound. Target enrollment is 181 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.